Medindia

X

Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th

Wednesday, May 14, 2008 General News J E 4
Advertisement
PRINCETON, N.J., May 13 Pharmasset, Inc.(Nasdaq: VRUS) management will present at the Rodman & Renshaw 5th AnnualGlobal Healthcare Conference being held from May 19-20, 2008 at the LeMeridien Beach Plaza Hotel in Monte Carlo, Monaco. Schaefer Price,Pharmasset's Chief Executive Officer, will provide an overview of the companyon Tuesday, May 20, 2008 at 11:00 AM (CEST) in the Zephyr Salon.

To access a simultaneous webcast of Mr. Price's overview via the internet,log on to the "Events & Presentations" section of the Investor Center onPharmasset's website at http://investor.pharmasset.com/events.cfm. Pleaseconnect to the website at least ten minutes prior to the start of thepresentation to ensure adequate time for a reliable connection and anysoftware download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website forthirty days following the conference. The investor presentation will beavailable for download in PDF format immediately following the presentation inthe "Events & Presentations" section of the Investor Center on Pharmasset'swebsite at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed todiscovering, developing and commercializing novel drugs to treat viralinfections. Pharmasset's primary focus is on the development of oraltherapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus(HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine,for the treatment of chronic HBV infection, is enrolling Phase 3 clinicaltrials for registration in North, Central and South America and Europe.Clevudine is already approved for HBV in South Korea and marketed by BukwangPharmaceuticals in South Korea under the brand name Levovir. R7128, an oraltreatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial incombination with Pegasys(R) plus Copegus(R) through a strategic collaborationwith Roche. Racivir, which is being developed for the treatment of HIV incombination with other approved HIV drugs, has completed a Phase 2 clinicaltrial.Pegasys(R) and Copegus(R) are registered trademarks of Roche. Contact Alan Roemer, Vice President Investor Relations & Corporate Communications alan.roemer@pharmasset.com Office: +1 (609) 613-4125

SOURCE Pharmasset, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
United American Healthcare Corporation Announces F...
S
IRIDEX Reports First Quarter 2008 Financial Result...